• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
EGFR-Directed Therapy in Lung Cancer

EGFR-Directed Therapy in Lung Cancer

9781009342308
107.10 zł
96.39 zł Save 10.71 zł
Lowest price within 30 days before promotion: 96.39 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).
Product Details
97930
9781009342308
9781009342308

Data sheet

Publication date
2023
Issue number
1
Cover
paperback
Pages count
75
Dimensions (mm)
152.00 x 228.00
Weight (g)
80
  • 1.Structural biology and mechanism of activation of EGFR; 2. EGFR-associated oncogenesis; 3. Tyrosine kinase inhibitors (TKIs) as targeted treatment for EGFR-mutant NSCLC; 4. EGFR-TKIs as adjuvant or neoadjuvant therapy; 5. EGFR-Exon 20 insertion mutations; 6. Resistance mechanisms and therapies in metastatic resistant EGFR-NSCLC; 7. Uncommon EGFR-activating mutations; 8. Immunotherapy in metastatic EGFR-mutant NSCLC; 9. Management of CNS disease and oligometastatic EGFR-mutant NSCLC; 10. ctDNA in EGFR-mutant NSCLC; 11. Guidelines and recommendations for EGFR-mutant NSCLC; References.
Comments (0)